BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Scarozza P, Schmitt H, Monteleone G, Neurath MF, Atreya R. Oligonucleotides-A Novel Promising Therapeutic Option for IBD. Front Pharmacol 2019;10:314. [PMID: 31068803 DOI: 10.3389/fphar.2019.00314] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Zhang G, Zhang C, Sun J, Xiong Y, Wang L, Chen D. Phytochemical Regulation of RNA in Treating Inflammatory Bowel Disease and Colon Cancer: Inspirations from Cell and Animal Studies. J Pharmacol Exp Ther 2021;376:464-72. [PMID: 33397676 DOI: 10.1124/jpet.120.000354] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Zhang W, Michalowski CB, Beloqui A. Oral Delivery of Biologics in Inflammatory Bowel Disease Treatment. Front Bioeng Biotechnol 2021;9:675194. [PMID: 34150733 DOI: 10.3389/fbioe.2021.675194] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Weng Y, Huang Q, Li C, Yang Y, Wang X, Yu J, Huang Y, Liang XJ. Improved Nucleic Acid Therapy with Advanced Nanoscale Biotechnology. Mol Ther Nucleic Acids 2020;19:581-601. [PMID: 31927331 DOI: 10.1016/j.omtn.2019.12.004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 9.7] [Reference Citation Analysis]
4 Chen K, Lou Y, Zhu Y. Tong Xie Yao Fang: A Classic Chinese Medicine Prescription with Potential for the Treatment of Ulcerative Colitis. Evid Based Complement Alternat Med 2021;2021:5548764. [PMID: 34211567 DOI: 10.1155/2021/5548764] [Reference Citation Analysis]
5 Lin WC, Fessler MB. Regulatory mechanisms of neutrophil migration from the circulation to the airspace. Cell Mol Life Sci 2021;78:4095-124. [PMID: 33544156 DOI: 10.1007/s00018-021-03768-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Yamamoto-Furusho JK, Parra-Holguín NN. Emerging therapeutic options in inflammatory bowel disease. World J Gastroenterol 2021; 27(48): 8242-8261 [DOI: 10.3748/wjg.v27.i48.8242] [Reference Citation Analysis]
7 Marafini I, Monteleone G. Therapeutic Oligonucleotides for Patients with Inflammatory Bowel Diseases. Biologics 2020;14:47-51. [PMID: 32606588 DOI: 10.2147/BTT.S257638] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Fattal E, Fay F. Nanomedicine-based delivery strategies for nucleic acid gene inhibitors in inflammatory diseases. Adv Drug Deliv Rev 2021;175:113809. [PMID: 34033819 DOI: 10.1016/j.addr.2021.05.019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
9 de Ceuninck van Capelle C, Spit M, Ten Dijke P. Current perspectives on inhibitory SMAD7 in health and disease. Crit Rev Biochem Mol Biol 2020;55:691-715. [PMID: 33081543 DOI: 10.1080/10409238.2020.1828260] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
10 Faber S, Lahoti T, Taylor E, Lewis L, Sapiro J, Toledo Sales V, Dragan Y, Jeffy B. Current Therapeutic Landscape and Safety Roadmap for Targeting the Aryl Hydrocarbon Receptor in Inflammatory Gastrointestinal Indications. Cells 2022;11:1708. [DOI: 10.3390/cells11101708] [Reference Citation Analysis]